ATG7 deficiency causes p53 activation, accumulation of defective mitochondria, proliferative defects, reduced tumor burden, conversion of adenomas and adenocarcinomas to oncocytomas, and increased mouse survival (51, 52). Here, TP53 is linked to oncocytic adenoma.